Literature DB >> 22965232

Stimulus bias provides evidence for conformational constraints in the structure of a G protein-coupled receptor.

Karen J Gregory1, Patrick M Sexton, Andrew B Tobin, Arthur Christopoulos.   

Abstract

A key characteristic of G protein-coupled receptors (GPCRs) is that they activate a plethora of signaling pathways. It is now clear that a GPCR coupling to these pathways can be regulated selectively by ligands that differentially drive signaling down one pathway in preference to another. This concept, termed stimulus bias, is revolutionizing receptor biology and drug discovery by providing a means of selectively targeting receptor signaling pathways that have therapeutic impact. Herein, we utilized a novel quantitative method that determines stimulus bias of synthetic GPCR ligands in a manner that nullifies the impact of both the cellular background and the "natural bias" of the endogenous ligand. By applying this method to the M(2) muscarinic acetylcholine receptor, a prototypical GPCR, we found that mutation of key residues (Tyr-80(2.61) and Trp-99(3.28)) in an allosteric binding pocket introduces stimulus bias in response to the atypical ligands AC-42 (4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)piperidine HCl) and 77-LH-28-1 (1-(3-(4-butyl-1-piperidinyl)propyl)- 3,3-dihydro-2(1H)-quinolinone). By comparing stimulus bias factors among receptor internalization, G protein activation, extracellular-regulated protein kinase 1/2 (ERK1/2) signaling, and receptor phosphorylation, we provide evidence that Tyr-80(2.61) and Trp-99(3.28) act either as molecular switches or as gatekeeper residues that introduce constraints limiting the active conformation of the M(2) muscarinic acetylcholine receptor and thereby regulate stimulus bias. Furthermore, we provide evidence that downstream signaling pathways previously considered to be related to each other (i.e. receptor phosphorylation, internalization, and activation of ERK1/2) can act independently.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22965232      PMCID: PMC3481307          DOI: 10.1074/jbc.M112.408534

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Discovery of an ectopic activation site on the M(1) muscarinic receptor.

Authors:  Tracy A Spalding; Carol Trotter; Niels Skjaerbaek; Terri L Messier; Erika A Currier; Ethan S Burstein; Donghui Li; Uli Hacksell; Mark R Brann
Journal:  Mol Pharmacol       Date:  2002-06       Impact factor: 4.436

2.  Application of a kinetic model to the apparently complex behavior of negative and positive allosteric modulators of muscarinic acetylcholine receptors.

Authors:  Vimesh Avlani; Lauren T May; Patrick M Sexton; Arthur Christopoulos
Journal:  J Pharmacol Exp Ther       Date:  2004-01-07       Impact factor: 4.030

3.  N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity.

Authors:  Cyrille Sur; Pierre J Mallorga; Marion Wittmann; Marlene A Jacobson; Danette Pascarella; Jacinta B Williams; Philip E Brandish; Douglas J Pettibone; Edward M Scolnick; P Jeffrey Conn
Journal:  Proc Natl Acad Sci U S A       Date:  2003-10-31       Impact factor: 11.205

4.  Historical review: a brief history and personal retrospective of seven-transmembrane receptors.

Authors:  Robert J Lefkowitz
Journal:  Trends Pharmacol Sci       Date:  2004-08       Impact factor: 14.819

5.  Operational models of pharmacological agonism.

Authors:  J W Black; P Leff
Journal:  Proc R Soc Lond B Biol Sci       Date:  1983-12-22

6.  Serotonergic antagonists differentially inhibit spontaneous activity and decrease ligand binding capacity of the rat 5-hydroxytryptamine type 2C receptor in Sf9 cells.

Authors:  J Labrecque; A Fargin; M Bouvier; P Chidiac; M Dennis
Journal:  Mol Pharmacol       Date:  1995-07       Impact factor: 4.436

7.  Constitutively active 5-hydroxytryptamine2C receptors reveal novel inverse agonist activity of receptor ligands.

Authors:  E L Barker; R S Westphal; D Schmidt; E Sanders-Bush
Journal:  J Biol Chem       Date:  1994-04-22       Impact factor: 5.157

8.  Multiple active states and oligomerization of CCR5 revealed by functional properties of monoclonal antibodies.

Authors:  Cédric Blanpain; Jean-Marie Vanderwinden; Josef Cihak; Valérie Wittamer; Emmanuel Le Poul; Hassan Issafras; Manfred Stangassinger; Gilbert Vassart; Stefano Marullo; Detlef Schlndorff; Marc Parmentier; Matthias Mack
Journal:  Mol Biol Cell       Date:  2002-02       Impact factor: 4.138

9.  Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2.

Authors:  Huijun Wei; Seungkirl Ahn; Sudha K Shenoy; Sadashiva S Karnik; László Hunyady; Louis M Luttrell; Robert J Lefkowitz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-08-29       Impact factor: 11.205

10.  Probing of the location of the allosteric site on m1 muscarinic receptors by site-directed mutagenesis.

Authors:  H Matsui; S Lazareno; N J Birdsall
Journal:  Mol Pharmacol       Date:  1995-01       Impact factor: 4.436

View more
  12 in total

1.  Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists.

Authors:  Iness Charfi; Karim Nagi; Ouissame Mnie-Filali; Dominic Thibault; Gianfranco Balboni; Peter W Schiller; Louis-Eric Trudeau; Graciela Pineyro
Journal:  Cell Mol Life Sci       Date:  2014-04       Impact factor: 9.261

2.  Endocytic profiles of δ-opioid receptor ligands determine the duration of rapid but not sustained cAMP responses.

Authors:  Hanieh Bagheri Tudashki; Derek N Robertson; Peter W Schiller; Graciela Pineyro
Journal:  Mol Pharmacol       Date:  2013-10-30       Impact factor: 4.436

3.  β2-Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle--ligand-directed signalling or a reflection of system complexity?

Authors:  Bronwyn A Evans; Dana S Hutchinson; Roger J Summers
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-05-09       Impact factor: 3.000

Review 4.  Mechanistic analysis of the function of agonists and allosteric modulators: reconciling two-state and operational models.

Authors:  David Roche; Debora Gil; Jesús Giraldo
Journal:  Br J Pharmacol       Date:  2013-07       Impact factor: 8.739

5.  Molecular mechanisms of bitopic ligand engagement with the M1 muscarinic acetylcholine receptor.

Authors:  Peter Keov; Laura López; Shane M Devine; Celine Valant; J Robert Lane; Peter J Scammells; Patrick M Sexton; Arthur Christopoulos
Journal:  J Biol Chem       Date:  2014-07-08       Impact factor: 5.157

Review 6.  Non-visual Opsins and Novel Photo-Detectors in the Vertebrate Inner Retina Mediate Light Responses Within the Blue Spectrum Region.

Authors:  Natalia A Marchese; Maximiliano N Rios; Mario E Guido; Luis P Morera; Nicolás M Diaz; Eduardo Garbarino-Pico; María Ana Contin
Journal:  Cell Mol Neurobiol       Date:  2020-11-24       Impact factor: 5.046

7.  G protein signaling-biased mu opioid receptor agonists that produce sustained G protein activation are noncompetitive agonists.

Authors:  Edward L Stahl; Cullen L Schmid; Agnes Acevedo-Canabal; Cai Read; Travis W Grim; Nicole M Kennedy; Thomas D Bannister; Laura M Bohn
Journal:  Proc Natl Acad Sci U S A       Date:  2021-11-30       Impact factor: 12.779

Review 8.  Non-traditional roles of G protein-coupled receptors in basic cell biology.

Authors:  Xin Zhang; Ulrike S Eggert
Journal:  Mol Biosyst       Date:  2013-04-05

Review 9.  Recent developments in biased agonism.

Authors:  James W Wisler; Kunhong Xiao; Alex R B Thomsen; Robert J Lefkowitz
Journal:  Curr Opin Cell Biol       Date:  2013-11-20       Impact factor: 8.382

10.  The pharmacology of TUG-891, a potent and selective agonist of the free fatty acid receptor 4 (FFA4/GPR120), demonstrates both potential opportunity and possible challenges to therapeutic agonism.

Authors:  Brian D Hudson; Bharat Shimpukade; Amanda E Mackenzie; Adrian J Butcher; John D Pediani; Elisabeth Christiansen; Helen Heathcote; Andrew B Tobin; Trond Ulven; Graeme Milligan
Journal:  Mol Pharmacol       Date:  2013-08-26       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.